Browse by Series:

FDA Approval of Adjuvant Dabrafenib/Trametinib in BRAF+ Melanoma

Gina Columbus
Published: Monday, Apr 30, 2018



Hello and welcome to OncLive News Network, Breaking News. I'm Gina Columbus.

The FDA has granted an approval to dabrafenib combined with trametinib as an adjuvant treatment for patients with BRAF V600E- or V600K-positive stage III melanoma following complete resection.

The approval is based on findings from the phase III COMBI-AD study, in which adjuvant treatment with dabrafenib and trametinib reduced the risk of relapse or death by 53% compared with placebo for patients with BRAF-mutant stage III melanoma.

After a median follow-up of 2.8 years, the 3-year relapse-free survival rate with dabrafenib and trametinib was 58% compared with 39% for placebo.

The median relapse-free survival was not reached with the combination versus 16.6 months for placebo; however, RFS was improved with dabrafenib plus trametinib across all subgroups.

For more breaking news, subscribe to email alerts from OncLive.com. Thank you for watching! I'm Gina Columbus.
 
SELECTED
LANGUAGE
Slider Left
Slider Right


Hello and welcome to OncLive News Network, Breaking News. I'm Gina Columbus.

The FDA has granted an approval to dabrafenib combined with trametinib as an adjuvant treatment for patients with BRAF V600E- or V600K-positive stage III melanoma following complete resection.

The approval is based on findings from the phase III COMBI-AD study, in which adjuvant treatment with dabrafenib and trametinib reduced the risk of relapse or death by 53% compared with placebo for patients with BRAF-mutant stage III melanoma.

After a median follow-up of 2.8 years, the 3-year relapse-free survival rate with dabrafenib and trametinib was 58% compared with 39% for placebo.

The median relapse-free survival was not reached with the combination versus 16.6 months for placebo; however, RFS was improved with dabrafenib plus trametinib across all subgroups.

For more breaking news, subscribe to email alerts from OncLive.com. Thank you for watching! I'm Gina Columbus.
 
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Immunotherapeutic Strategies with the Potential to Transform Treatment for Genitourinary CancersAug 29, 20191.0
Publication Bottom Border
Border Publication
x